Which hedge funds own IBRX? IMMUNITYBIO INC, Q2 2026 13F holders
35 tracked hedge funds disclosed a position in IBRX (IMMUNITYBIO INC) in their Q2 2026 13F filings, worth $334.3m in total. The largest holder by portfolio weight is PharVision Advisers, LLC at 1.8% of its book. 16 opened a new position this quarter: PharVision Advisers, LLC, CenterBook Partners LP, Militia Capital Management LLC, Trexquant Investment LP. 6 exited: Arrowpoint Investment Partners (Singapore) Pte. Ltd., Stilwell Value LLC, CenterStar Asset Management, LLC.
- 35
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 16
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 6
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $30.5m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $6.0m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $334m
- Combined value Sum of the holders' reported positions in the security.
- 2.8%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 0.5% | $315k |
| Stilwell Value LLC | 0.4% | $614k |
| CenterStar Asset Management, LLC | 0.2% | $165k |
| Tudor Investment Corp ET AL | 0.02% | $4.4m |
| Mirabella Financial Services LLP | 0.01% | $151k |
| SummitTX Capital, L.P. | 0.01% | $374k |